Omega Fund VI, L.P. - Nov 2, 2023 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
10%+ Owner
Signature
/s/ Otello Stampacchia, authorized signatory
Stock symbol
LXEO
Transactions as of
Nov 2, 2023
Transactions value $
$0
Form type
3
Date filed
11/2/2023, 09:40 PM
Previous filing
Oct 14, 2021
Next filing
Nov 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LXEO Series A convertible preferred stock Nov 2, 2023 Common Stock 1.42M Direct F1, F2
holding LXEO Series B convertible preferred stock Nov 2, 2023 Common Stock 247K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 basis at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.
F2 The reported securities are held by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI.
F3 Each share of Series B convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 basis at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. Excludes shares of Common Stock issuable upon the closing of the Issuer's initial public offering pursuant to anti-dilution adjustment provisions of the Series B convertible preferred stock. The shares have no expiration date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney